{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T12:33:34Z","timestamp":1781008414526,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,9]]},"DOI":"10.7759\/cureus.33575","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T07:04:28Z","timestamp":1673334268000},"source":"Crossref","is-referenced-by-count":18,"title":["Herd Immunity to Fight Against COVID-19: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Yasha N","family":"Suryawanshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia A","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26424","article-title":"Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes","volume":"93","author":"Li J","year":"2021","unstructured":"Li J, Huang DQ, Zou B, et al.. Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2021, 93:1449-58. 10.1002\/jmv.26424","journal-title":"J Med Virol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.250.271","article-title":"The coronavirus disease 2019 (COVID-19) pandemic","volume":"250","author":"Baloch S","year":"2020","unstructured":"Baloch S, Baloch MA, Zheng T, Pei X. The coronavirus disease 2019 (COVID-19) pandemic. Tohoku J Exp Med. 2020, 250:271-8. 10.1620\/tjem.250.271","journal-title":"Tohoku J Exp Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2021.12.014","article-title":"The SARS-CoV-2 mutations versus vaccine effectiveness: new opportunities to new challenges","volume":"15","author":"Malik JA","year":"2022","unstructured":"Malik JA, Ahmed S, Mir A, et al.. The SARS-CoV-2 mutations versus vaccine effectiveness: new opportunities to new challenges. J Infect Public Health. 2022, 15:228-40. 10.1016\/j.jiph.2021.12.014","journal-title":"J Infect Public Health"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.01.001","article-title":"Recombinant protein vaccines, a proven approach against coronavirus pandemics","volume":"170","author":"Pollet J","year":"2021","unstructured":"Pollet J, Chen WH, Strych U. Recombinant protein vaccines, a proven approach against coronavirus pandemics. Adv Drug Deliv Rev. 2021, 170:71-82. 10.1016\/j.addr.2021.01.001","journal-title":"Adv Drug Deliv Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.04.012","article-title":"Herd immunity: understanding COVID-19","volume":"52","author":"Randolph HE","year":"2020","unstructured":"Randolph HE, Barreiro LB. Herd immunity: understanding COVID-19. Immunity. 2020, 52:737-41. 10.1016\/j.immuni.2020.04.012","journal-title":"Immunity"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqaa272","article-title":"Herd immunity to COVID-19","volume":"155","author":"Kadkhoda K","year":"2021","unstructured":"Kadkhoda K. Herd immunity to COVID-19. Am J Clin Pathol. 2021, 155:471-2. 10.1093\/ajcp\/aqaa272","journal-title":"Am J Clin Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2020.0275","article-title":"Segmentation and shielding of the most vulnerable members of the population as elements of an exit strategy from COVID-19 lockdown","volume":"376","author":"van Bunnik BA","year":"2021","unstructured":"van Bunnik BA, Morgan AL, Bessell PR, et al.. Segmentation and shielding of the most vulnerable members of the population as elements of an exit strategy from COVID-19 lockdown. Philos Trans R Soc Lond B Biol Sci. 2021, 376:20200275. 10.1098\/rstb.2020.0275","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5802\/crbiol.41","article-title":"COVID-19: individual and herd immunity","volume":"344","author":"Bach JF","year":"2021","unstructured":"Bach JF, Berche P, Chatenoud L, Costagliola D, Valleron AJ. COVID-19: individual and herd immunity. C R Biol. 2021, 344:7-18. 10.5802\/crbiol.41","journal-title":"C R Biol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-021-00915-3","article-title":"Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis","volume":"10","author":"Liu Q","year":"2021","unstructured":"Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect Dis Poverty. 2021, 10:132. 10.1186\/s40249-021-00915-3","journal-title":"Infect Dis Poverty"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.027","article-title":"Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries","volume":"80","author":"Kwok KO","year":"2020","unstructured":"Kwok KO, Lai F, Wei WI, Wong SY, Tang JW. Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries. J Infect. 2020, 80:e32-3. 10.1016\/j.jinf.2020.03.027","journal-title":"J Infect"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.809244","article-title":"SARS-CoV-2 variants, vaccines, and host immunity","volume":"12","author":"Mistry P","year":"2021","unstructured":"Mistry P, Barmania F, Mellet J, et al.. SARS-CoV-2 variants, vaccines, and host immunity. Front Immunol. 2021, 12:809244. 10.3389\/fimmu.2021.809244","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.37201\/req\/080.2020","article-title":"[Repetition of microbiological tests in suspect of SARS-CoV-2 infection: utility of a score based on clinical probability]","volume":"33","author":"Pardo Lledias J","year":"2020","unstructured":"Pardo Lledias J, Ayarza L, Gonz\u00e1lez-Garc\u00eda P, et al.. [Repetition of microbiological tests in suspect of SARS-CoV-2 infection: utility of a score based on clinical probability]. Rev Esp Quimioter. 2020, 33:410-4. 10.37201\/req\/080.2020","journal-title":"Rev Esp Quimioter"},{"key":"ref13","unstructured":"WHO coronavirus (COVID-19) dashboard with vaccination data. (2022). Accessed. October 8, 2022: https:\/\/covid19.who.int\/table."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01817","article-title":"The long road toward COVID-19 herd immunity: vaccine platform technologies and mass immunization strategies","volume":"11","author":"Frederiksen LS","year":"2020","unstructured":"Frederiksen LS, Zhang Y, Foged C, Thakur A. The long road toward COVID-19 herd immunity: vaccine platform technologies and mass immunization strategies. Front Immunol. 2020, 11:1817. 10.3389\/fimmu.2020.01817","journal-title":"Front Immunol"},{"key":"ref15","article-title":"COVID-19 vaccines and herd immunity: perspectives, challenges and prospects","volume":"43","author":"Wong RS","year":"2021","unstructured":"Wong RS. COVID-19 vaccines and herd immunity: perspectives, challenges and prospects. Malays J Pathol. 2021, 43:203-17.","journal-title":"Malays J Pathol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdab192","article-title":"The role of religiosity in COVID-19 vaccine hesitancy","volume":"43","author":"Garcia LL","year":"2021","unstructured":"Garcia LL, Yap JF. The role of religiosity in COVID-19 vaccine hesitancy. J Public Health (Oxf). 2021, 43:e529-30. 10.1093\/pubmed\/fdab192","journal-title":"J Public Health (Oxf)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2021.36.e227","article-title":"Pediatric and parents' attitudes towards COVID-19 vaccines and intention to vaccinate for children","volume":"36","author":"Choi SH","year":"2021","unstructured":"Choi SH, Jo YH, Jo KJ, Park SE. Pediatric and parents' attitudes towards COVID-19 vaccines and intention to vaccinate for children. J Korean Med Sci. 2021, 36:e227. 10.3346\/jkms.2021.36.e227","journal-title":"J Korean Med Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2021.08.007","article-title":"COVID-19 vaccination during pregnancy: coverage and safety","volume":"226","author":"Blakeway H","year":"2022","unstructured":"Blakeway H, Prasad S, Kalafat E, et al.. COVID-19 vaccination during pregnancy: coverage and safety. Am J Obstet Gynecol. 2022, 226:236.e1-e14. 10.1016\/j.ajog.2021.08.007","journal-title":"Am J Obstet Gynecol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(20)30564-2","article-title":"COVID-19 vaccination for people with severe mental illness: why, what, and how?","volume":"8","author":"Mazereel V","year":"2021","unstructured":"Mazereel V, Van Assche K, Detraux J, De Hert M. COVID-19 vaccination for people with severe mental illness: why, what, and how?. Lancet Psychiatry. 2021, 8:444-50. 10.1016\/S2215-0366(20)30564-2","journal-title":"Lancet Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.12.047","article-title":"mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach","volume":"9","author":"Banerji A","year":"2021","unstructured":"Banerji A, Wickner PG, Saff R, et al.. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract. 2021, 9:1423-37. 10.1016\/j.jaip.2020.12.047","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.884879","article-title":"An update on protective effectiveness of immune responses after recovery from COVID-19","volume":"13","author":"Soleimanian S","year":"2022","unstructured":"Soleimanian S, Alyasin S, Sepahi N, Ghahramani Z, Kanannejad Z, Yaghobi R, Karimi MH. An update on protective effectiveness of immune responses after recovery from COVID-19. Front Immunol. 2022, 13:884879. 10.3389\/fimmu.2022.884879","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2022.112911","article-title":"SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity","volume":"209","author":"Pilz S","year":"2022","unstructured":"Pilz S, Theiler-Schwetz V, Trummer C, Krause R, Ioannidis JP. SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity. Environ Res. 2022, 209:112911. 10.1016\/j.envres.2022.112911","journal-title":"Environ Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00407-0","article-title":"Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?","volume":"9","author":"Milne G","year":"2021","unstructured":"Milne G, Hames T, Scotton C, Gent N, Johnsen A, Anderson RM, Ward T. Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?. Lancet Respir Med. 2021, 9:1450-66. 10.1016\/S2213-2600(21)00407-0","journal-title":"Lancet Respir Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13582","article-title":"Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses","volume":"204","author":"Jordan SC","year":"2021","unstructured":"Jordan SC. Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses. Clin Exp Immunol. 2021, 204:310-20. 10.1111\/cei.13582","journal-title":"Clin Exp Immunol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.610300","article-title":"Different innate and adaptive immune responses to SARS-CoV-2 infection of asymptomatic, mild, and severe cases","volume":"11","author":"Carsetti R","year":"2020","unstructured":"Carsetti R, Zaffina S, Piano Mortari E, et al.. Different innate and adaptive immune responses to SARS-CoV-2 infection of asymptomatic, mild, and severe cases. Front Immunol. 2020, 11:610300. 10.3389\/fimmu.2020.610300","journal-title":"Front Immunol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pulmoe.2021.03.008","article-title":"The immune response to SARS-CoV-2 and COVID-19 immunopathology - current perspectives","volume":"27","author":"Boechat JL","year":"2021","unstructured":"Boechat JL, Chora I, Morais A, Delgado L. The immune response to SARS-CoV-2 and COVID-19 immunopathology - current perspectives. Pulmonology. 2021, 27:423-37. 10.1016\/j.pulmoe.2021.03.008","journal-title":"Pulmonology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.08.001","article-title":"A comprehensive analysis of the efficacy and safety of COVID-19 vaccines","volume":"29","author":"Cai C","year":"2021","unstructured":"Cai C, Peng Y, Shen E, et al.. A comprehensive analysis of the efficacy and safety of COVID-19 vaccines. Mol Ther. 2021, 29:2794-805. 10.1016\/j.ymthe.2021.08.001","journal-title":"Mol Ther"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2118312119","article-title":"Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants","volume":"119","author":"Kingstad-Bakke B","year":"2022","unstructured":"Kingstad-Bakke B, Lee W, Chandrasekar SS, et al.. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants. Proc Natl Acad Sci U S A. 2022, 119:e2118312119. 10.1073\/pnas.2118312119","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref29","unstructured":"World Health Organization (WHO). (2022). Accessed. October 8, 2022: https:\/\/www.who.int."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03495-21","article-title":"Great expectations of COVID-19 herd immunity","volume":"13","author":"Giurgea LT","year":"2022","unstructured":"Giurgea LT, Morens DM. Great expectations of COVID-19 herd immunity. mBio. 2022, 13:e0349521. 10.1128\/mbio.03495-21","journal-title":"mBio"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00681-2","article-title":"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials","volume":"22","author":"Zeng G","year":"2022","unstructured":"Zeng G, Wu Q, Pan H, et al.. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2022, 22:483-95. 10.1016\/S1473-3099(21)00681-2","journal-title":"Lancet Infect Dis"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s13312-010-0095-1","article-title":"Efficacy and safety of therapeutic nutrition products for home based therapeutic nutrition for severe acute malnutrition a systematic review","volume":"47","author":"Gera T","year":"2010","unstructured":"Gera T. Efficacy and safety of therapeutic nutrition products for home based therapeutic nutrition for severe acute malnutrition a systematic review. Indian Pediatr. 2010, 47:709-18. 10.1007\/s13312-010-0095-1","journal-title":"Indian Pediatr"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-00728-2","article-title":"Five reasons why COVID herd immunity is probably impossible","volume":"591","author":"Aschwanden C","year":"2021","unstructured":"Aschwanden C. Five reasons why COVID herd immunity is probably impossible. Nature. 2021, 591:520-2. 10.1038\/d41586-021-00728-2","journal-title":"Nature"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s12553-022-00676-5","article-title":"A herd immunity approach to the COVID-19 pandemic?","volume":"12","author":"Takefuji Y","year":"2022","unstructured":"Takefuji Y. A herd immunity approach to the COVID-19 pandemic?. Health Technol (Berl). 2022, 12:1037-41. 10.1007\/s12553-022-00676-5","journal-title":"Health Technol (Berl)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2107692118","article-title":"Core concept: herd immunity is an important-and often misunderstood-public health phenomenon","volume":"118","author":"McDermott A","year":"2021","unstructured":"McDermott A. Core concept: herd immunity is an important-and often misunderstood-public health phenomenon. Proc Natl Acad Sci U S A. 2021, 118:e2107692118. 10.1073\/pnas.2107692118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-00083-2","article-title":"The herd-immunity threshold must be updated for multi-vaccine strategies and multiple variants","volume":"11","author":"Yadegari I","year":"2021","unstructured":"Yadegari I, Omidi M, Smith SR. The herd-immunity threshold must be updated for multi-vaccine strategies and multiple variants. Sci Rep. 2021, 11:22970. 10.1038\/s41598-021-00083-2","journal-title":"Sci Rep"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.epirev.a036121","article-title":"Herd immunity: history, theory, practice","volume":"15","author":"Fine PE","year":"1993","unstructured":"Fine PE. Herd immunity: history, theory, practice. Epidemiol Rev. 1993, 15:265-302. 10.1093\/oxfordjournals.epirev.a036121","journal-title":"Epidemiol Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/116952-herd-immunity-to-fight-against-covid-19-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:53:57Z","timestamp":1707508437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/116952-herd-immunity-to-fight-against-covid-19-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.33575","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,9]]}}}